Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infants from 12 months of age to 15 months of age.~2. Consent form signed by both parents or by the legal representative(s), properly informed about the study,~3. Parent(s) able to understand the protocol requirements and to fill in the Diary Card.~Exclusion Criteria:~1. Prior receipt of measles, mumps, rubella or varicella vaccine either alone or in combination vaccine,~2. Known or suspected clinical history of infection with measles, mumps, rubella, varicella or zoster,~3. Any known recent (≤30 days) exposure to measles, mumps or rubella,~4. Any known recent (≤30 days) exposure to varicella or zoster involving:~5. Any recent (≤3 days) history of febrile illness (rectal temperature ≥38.0°C),~6. Active untreated tuberculosis,~7. Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems,~8. Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,~9. Any previous (≤150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through visit 3,~10. Any recent receipt of an inactivated or a live vaccine (≤ 30 days) or scheduled vaccination through visit 3

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).